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Background—Hypertrophic cardiomyopathy (HCM), typically characterized by asymmetrical left ventricular hypertrophy,
frequently is caused by mutations in sarcomeric proteins. We studied if changes in sarcomeric properties in HCM
depend on the underlying protein mutation.
Methods and Results—Comparisons were made between cardiac samples from patients carrying a MYBPC3 mutation
(MYBPC3mut; n17), mutation negative HCM patients without an identified sarcomere mutation (HCMmn; n11), and
nonfailing donors (n12). All patients had normal systolic function, but impaired diastolic function. Protein expression of
myosin binding protein C (cMyBP-C) was significantly lower in MYBPC3mut by 335%, and similar in HCMmn compared
with donor. cMyBP-C phosphorylation in MYBPC3mut was similar to donor, whereas it was significantly lower in HCMmn.
Troponin I phosphorylation was lower in both patient groups compared with donor. Force measurements in single
permeabilized cardiomyocytes demonstrated comparable sarcomeric dysfunction in both patient groups characterized by
lower maximal force generating capacity in MYBPC3mut and HCMmn, compared with donor (26.42.9, 28.03.7, and
37.22.3 kN/m2, respectively), and higher myofilament Ca2-sensitivity (EC502.50.2, 2.40.2, and 3.00.2 mol/L,
respectively). The sarcomere length-dependent increase in Ca2-sensitivity was significantly smaller in both patient groups
compared with donor (EC50: 0.460.04, 0.370.05, and 0.750.07 mol/L, respectively). Protein kinase A treatment
restored myofilament Ca2-sensitivity and length-dependent activation in both patient groups to donor values.
Conclusions—Changes in sarcomere function reflect the clinical HCM phenotype rather than the specific MYBPC3
mutation. Hypocontractile sarcomeres are a common deficit in human HCM with normal systolic left ventricular
function and may contribute to HCM disease progression. (Circ Heart Fail. 2012;5:36-46.)
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Hypertrophic cardiomyopathy (HCM), most often caused bymutations in genes encoding sarcomeric proteins, is a
major cause of morbidity and mortality affecting1:500 people
worldwide at a relatively young age.1,2 It often is characterized
by asymmetrical left ventricular (LV) hypertrophy, predomi-
nantly involving the interventricular septum, occurring in the
absence of other cardiac or systemic disease (such as hyperten-
sion or aortic stenosis). Clinical presentation is very heteroge-
neous in HCM as some patients reach old age with virtually no
complaints, while others progress to end-stage heart failure or
die at a young age from sudden cardiac arrest. To develop a
targeted treatment to prevent or delay HCM, it is highly relevant
to understand the pathophysiology of this disease.
Clinical Perspective on p 46
During the last 2 decades, many disease causing mutations
have been identified, mainly in genes encoding sarcomeric
proteins.3,4 Despite improved genetic testing the causal gene
mutation remains unidentified in over 40% of HCM patients.5
Furthermore, the pathophysiological mechanism leading from a
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genetic defect to cardiac dysfunction is currently largely un-
known. Recent studies have shown that even before hypertrophy
is overt, carriers of a HCM-causing sarcomere mutation dem-
onstrate signs of cardiac dysfunction.6–9 Echocardiographic
strain analysis in preclinical HCM patients with mutations in
genes encoding -myosin heavy chain (MYH7), cardiac myosin
binding protein C (MYBPC3), cardiac troponin T (TNNT2),
cardiac troponin I (TNNI3), and -tropomyosin (TPM1) demon-
strated a reduced early diastolic velocity.6 Systolic strain and
strain rates were not different from controls in preclinical HCM
patients, while systolic function was diminished in HCM pa-
tients with manifest ventricular hypertrophy.6 Cardiac magnetic
resonance evaluation of carriers with a Dutch founder mutation
in MYBPC3 or a mutation in TPM1 confirmed diastolic dys-
function at the preclinical stage, evident from slower diastolic
circumferential strain rate in septal and lateral regions of the
LV.8 Tissue Doppler imaging in MYBPC3 mutation carriers
without LV hypertrophy also revealed diastolic abnormalities as
a first feature of preclinical HCM.9 Furthermore, structural
abnormalities consisting of crypts were discerned in a large
percentage of these preclinical patients.10 Fibrosis, a hallmark of
overt HCM, was not visible in preclinical HCM, but serum level
of the profibrotic C-terminal propeptide of type I collagen
already was elevated.11 These data indicate that sarcomeric
mutations initiate early modifications in myocardial structure
and function.
Recently we have provided evidence for sarcomeric dysfunc-
tion in manifest HCM patients with truncating MYBPC3 founder
mutations (c.2373dupG and c.2864_2865delCT).12 The sarco-
meric dysfunction included a reduction in maximal force gen-
erating capacity and a higher myofilament Ca2-sensitivity
compared with nonfailing human myocardium, which may be
the result of altered sarcomeric protein composition as we
observed haploinsufficiency (ie, reduced cardiac myosin binding
protein C [cMyBP-C] protein expression) in these patients.
Haploinsufficiency was confirmed and extended to HCM caused
by missense MYBPC3 mutations.13 In the present study we
investigated if the changes in sarcomeric function and protein
composition are specific for the MYBPC3 mutations or are part
of the more general clinical HCM phenotype.
To this end sarcomeric protein analysis was combined with
force measurements in cardiac cells from patients with LV
outflow tract obstruction harboring a MYBPC3 mutation, and in
mutation negative HCM patients in whom no mutation was
identified on screening of 9 genes that most frequently cause
HCM.14 To investigate if sarcomere responsiveness to increased
cardiac stress (as occurs during exercise) is preserved in HCM
patients, force was measured at 2 different sarcomere lengths (ie,
Frank-Starling mechanism) and after treatment with protein
kinase A (PKA; ie, -adrenergic receptor stimulation).
Our study showed depressed maximal force, higher Ca2-
sensitivity, and perturbed length-dependent activation of
sarcomeres in HCM patients with normal LV function and
impaired diastolic function irrespective of the mutant protein.
The high myofilament Ca2-sensitivity may in part underlie
LV diastolic dysfunction, while the hypocontractile sarco-
meres (lower maximal force and impaired length-dependent
activation) may contribute to disease progression in HCM.
Methods
An extended version of the methods section is provided as an online
supplement (see the online-only supplement).
Myocardial Samples
Cardiac tissue was obtained from the LV septum of 17 HCM patients
with a MYBPC3 mutation (MYBPC3mut group), and 11 mutation
negative HCM patients after detailed sequencing of 9 HCM-
associated genes (MYBPC3, MYH7, TNNT2, TNNI3, MYL2, MYL3,
ACTC, TPM1 and CSRP3;14 HCMmn group) that underwent myec-
tomy to relieve LV outflow obstruction (Morrow procedure). The
MYBPC3mut group comprised patients with truncating mutations
c.2373dupG (n9) and 2864-_2865delCT (n4), and splice site
mutations c.927 to 2AG (n3) and c.1458 to 1GC (n1).
Echocardiographic and clinical data of the patients are given in the
Table. Nonfailing LV cardiac tissue was obtained from donor hearts
(n12; 13 to 65 years of age, mean 425 years; 8/4 male/female).
The study protocol was approved by the local ethics committees and
written informed consent was obtained.
Protein Analysis and Isometric
Force Measurements
Analysis of sarcomeric protein phosphorylation15–20 and force mea-
surements on single cardiomyocytes21 was performed as described
previously.
Data Analysis
Data are presented as meansSEM. Cardiomyocyte force values
were averaged per sample. The Shapiro–Wilk test was used to
analyze if data from different groups followed a normal distribution.
When data were distributed normally and showed equal variances,
mean values for MYBPC3mut, HCMmn, and donor samples were
compared using a 1-way ANOVA followed by a Bonferroni post
test. When data were not distributed normally or showed unequal
variances, mean values for MYBPC3mut, HCMmn and donor samples
were compared using a nonparametric Kruskal-Wallis test, followed
by a Dunn Multiple Comparison Test. The effect of Ca2 on force
development was tested in 2-way repeated measures ANOVA using
averaged data per heart. Effects of exogenous PKA treatment in
single cardiomyocytes were tested with repeated measures 2-way
ANOVA, or 2-way ANOVA followed by a Bonferroni post test.
P0.05 was considered significant.
Results
Clinical Characteristics
Hypertrophic obstructive cardiomyopathy was evident from
higher septal thickness (211 mm in both patient
groups; normal value 13 mm)22 and high LV outflow
tract pressure gradient (844 and 957 mm Hg; normal
value 30 mm Hg)23 in MYBPC3mut and HCMmn patients,
respectively (Table). LV systolic function was graded as
normal (grade 1) in all patients except 1, in whom mild (grade
2) LV systolic dysfunction was observed (MYBPC3mut pa-
tient 11). In contrast to the normal systolic function, impaired
relaxation was observed in all patients (30% stage 1, 60%
stage 2, and 10% stage 3 diastolic dysfunction).
Haploinsufficiency and Altered Phosphorylation
Pattern in MYBPC3mut
Figure 1A shows MYBPC3mut, HCMmn, and donor samples
separated by 1D-gel electrophoresis stained with SYPRO and
ProQ Diamond to determine cMyBP-C protein level (relative to
-actinin) and sarcomeric protein phosphorylation, respectively.
A significantly lower cMyBP-C protein level was found in
MYBPC3mut hearts compared with donor myocardium (Figure
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1B; P0.0001 in 1-way ANOVA), which was not observed in
HCMmn. Previous studies indicated ischemia-induced degrada-
tion of cMyBP-C at the N-terminus.24,25 To exclude that
cMyBP-C degradation underlies the lower expression of full-
length cMyBP-C in MYBPC3mut, Western blot analysis was
performed with a specific antibody directed at the N-terminus of
cMyBP-C. No degradation products were observed in any of the
samples from the patients (Figure 1C) and donors. Furthermore,
absence of smaller cMyBP-C products indicates absence of
truncated forms of cMyBP-C (encoded by the mutated allele) in
the sarcomeres.
Phosphorylation of cMyBP-C normalized to its own ex-
pression level did not differ from donor in MYBPC3mut,
while it was significantly lower in HCMmn (Figure 1D;
P0.001 in Kruskal-Wallis test). Figure 1E illustrates that,
when normalized to -actinin, the level of phosphorylated
cMyBP-C is independent of cMyBP-C expression in the
patient groups and significantly lower in both MYBPC3mut
and HCMmn compared with donor.
To further unravel the differences in cMyBP-C phosphor-
ylation between MYBPC3mut and HCMmn, we performed
Western blot analysis with phospho-specific antibodies (Fig-
ure 2A). The level of Ser273-phosphorylated cMyBP-C was
significantly lower in HCMmn compared with donor, while an
intermediate value was observed in MYBPC3mut (Figure 2B;
P0.04 in Kruskal-Wallis test). Ser282-phosphorylated
cMyBP-C also was significantly lower in HCMmn, but
unaltered in MYBPC3mut compared with donor (Figure 2B;
P0.04 in Kruskal-Wallis test). No significant difference
was present in Ser302-phosphorylated cMyBP-C among
groups (Figure 2B; P0.25 in 1-way ANOVA).
Phosphorylation of the other PKA target protein, cardiac
troponin (cTnI), was significantly lower in both patient
groups compared with donor (Figure 3A; P0.0001 in
Table. Patient Characteristics
MYBPC3 Mutation Age (Y) Sex LVOTPG ST Medication
MYBPC3mut
1 c.2373dupG 32 F 100 30 -blocker
2 c.2373dupG 39 F 60 20 CCB, diuretics
3 c.2373dupG 45 F 94 20 CCB
4 c.2373dupG 62 M 64 23 ATII, -blocker, statins
5 c.2373dupG 44 F 100 17 CCB
6 c.2373dupG 69 M 74 19 -blocker, diuretics, statins
7 c.2373dupG 57 F 74 24 -blocker
8 c.2373dupG 32 M 88 23 -blocker, CCB
9 c.2373dupG 60 M 77 23 -blocker, CCB
10 c.2864_2865delCT 42 M 116 23 CCB, vitamin D
11 c.2864_2865delCT 45 M 100 20 CCB, -blocker
12 c.2864_2865delCT 62 F 67 15 -blocker, diuretics, statins, AA
13 c.2864_2865delCT 62 F 112 17 -blocker, CCB, diuretics
14 c.927-2AG 22 M 71 30 -blocker, CCB
15 c.927-2AG 48 M 82 18 -blocker
16 c.927-2AG 37 M 61 19 -blocker
17 c.1458-1GC 41 F 92 22 -blocker, CCB
Mean 473 9 M/8F 844 211
HCMmn
1 46 F 105 24 -blocker, CCB
2 46 F 100 18 -blocker
3 46 M 100 16 -blocker
4 72 F 100 24 CCB
5 57 M 117 25 -blocker, CCB
6 75 F 137 20 CCB
7 52 M 67 22 -blocker, CCB
8 72 F 88 24 -blocker
9 65 F 85 19 CCB
10 49 M 61 20 -blocker, CCB
11 46 M 81 19 -blocker
Mean 574 5 M/6F 957 211
LVOTPG indicates left ventricular outflow tract pressure gradient in mm Hg; ST, septal thickness in mm; CCB, calcium channel blocker; ATII, angiotensin II receptor
antagonist; AA, antiarrhythmic agent.
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Kruskal-Wallis test). The level of PKA (Ser22/23)-phosphor-
ylated cTnI was significantly lower in both MYBPC3mut and
HCMmn compared with donor (Figure 3B; P0.0002 in
Kruskal-Wallis test), while signals at the protein kinase C site
Thr143 were extremely low in all groups (data not shown),
indicating that the lower overall cTnI phosphorylation in
patient samples compared with donor is mainly because of
lower phosphorylation at PKA sites. cTnI also was separated
on a Phos-tag polyacrylamide gel and subsequently stained
on Western blots with a cTnI specific antibody (Figure 3C).
This analysis yielded the distribution pattern of un- (0P),
mono- (1P), and bis- (2P) phosphorylated cTnI. The distri-
bution of the cTnI forms was significantly different among
the 3 groups (Figure 3D; tested in 2-way ANOVA; interac-
tion P0.05). The relative levels of un- and monophosphor-
ylated cTnI were higher in both HCM patient groups com-
pared with donor, while the proportion of bisphosphorylated cTnI
was lower, confirming the low overall cTnI phosphorylation ob-
served in these patients with ProQ analysis (Figure 3A).
Sarcomeric Dysfunction in Manifest HCM
Independent of MYBPC3 Mutation
Figure 4 shows force characteristics at a sarcomere length of
2.2 m. A lower average Fmax was found in MYBPC3mut
(26.42.9 kN/m2) and HCMmn samples (28.03.7 kN/m2),
compared with donor (37.22.3 kN/m2; P0.04 in 1-way
ANOVA). Figure 4A illustrates that the variability in Fmax was
relatively large among individual hearts. Likewise, Fpas varied
between hearts (Figure 4B) and tended to be somewhat higher in
MYBPC3mut (3.50.6 kN/m2) compared with HCMmn
(2.40.3 kN/m2) and donor (2.40.3 kN/m2), but the difference
was not significant (P0.68 in Kruskal-Wallis test).
Figure 4C shows force-calcium relations for all groups at a
sarcomere length of 2.2 m; force at submaximal [Ca2] was
normalized to maximal force at saturating [Ca2]. The
force-calcium relation in both patient groups was shifted to
the left compared with donor, indicating a higher myofila-
ment Ca2-sensitivity. The relations between force and
[Ca2] were significantly different among groups (interaction
Figure 1. Cardiac myosin binding protein C expression and phosphorylation. A, Cardiac samples separated by 1D-gel electrophoresis
and stained with SYPRO for analysis of cardiac myosin binding protein C (cMyBP-C) expression relative to -actinin, and with ProQ
Diamond for analysis of cMyBP-C and cardiac troponin I protein phosphorylation. B, Protein level of cMyBP-C was significantly lower
in MYBPC3mut compared with HCMmn and donor samples. C, Western blot analysis of cMyBP-C did not reveal truncated or degrada-
tion products with a specific antibody. D, Phosphorylation of cMyBP-C (normalized to its own expression level) was significantly lower
in HCMmn samples compared with MYBPC3mut and donor tissue. E, Phosphorylated cMyBP-C (normalized to -actinin), as an indirect
measure of kinase activity, plotted against cMyBP-C expression (normalized to -actinin) to illustrate that the degree of phosphorylation
is independent of cMyBP-C protein expression in the HCM patient groups, and significantly lower compared with nonfailing donor
myocardium. *P0.05 versus donor; #P0.05 versus patient group Dunn Multiple Comparison Test or Bonferroni post test.
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P0.05 in 2-way repeated measures ANOVA). The average
value for Ca2-sensitivity (indicated as EC50, which is the
[Ca2] required to reach 50% of Fmax) was significantly
lower in MYBPC3mut (2.50.2 mol/L) and HCMmn
(2.40.2 mol/L) compared with donor (3.00.2 mol/L;
Figure 4D; P0.04 in 1-way ANOVA). In addition, the
steepness (nH) of the force-calcium relation was significantly
lower in both patient groups (3.10.0.2 and 3.00.0.2 in
MYBPC3mut and HCMmn, respectively) compared with donor
(3.70.1; Figure 4E; P0.02 in Kruskal-Wallis test).
Myofilament Length-Dependent Activation
To assess the length-dependent activation of myofilament con-
traction, force was measured at a sarcomere length of 1.8 and
2.2 m (Figure 5A) in 43 cells from 13 MYBPC3mut hearts, 36
cells from 8 HCMmn hearts, and 32 cardiomyocytes from 9
donor hearts. These measurements were performed in subsets of
patients with clinical characteristics similar to the group aver-
ages, because of tissue availability. In all groups, an increase in
sarcomere length from 1.8 to 2.2 m increased maximal force,
passive force, and Ca2-sensitivity of the sarcomeres. The
relations between force and [Ca2] at both sarcomere lengths
were significantly different among groups (interaction P0.05
in 2-way repeated measures ANOVA; Figure 5B). Of note, the
increase in Ca2-sensitivity on an increase in sarcomere length
from 1.8 to 2.2 m (ie, EC50) was significantly smaller in both
patient groups (0.460.04 and 0.370.05 mol/L in
MYBPC3mut and HCMmn, respectively) compared with donor
(0.760.06 mol/L; Figure 5C; P0.002 in Kruskal-Wallis
test).
The resultant of a lower Fmax and higher myofilament
Ca2-sensitivity in patient groups compared with donor is
illustrated in Figure 5B. This Figure shows that the sarcomeric
properties in patient groups (ie, lower Fmax, higher Ca2-
sensitivity, and lower nH) result in depressed force development
at [Ca2] above 3.3 and 2.5 mol/L at a sarcomere length of 1.8
and 2.2 m, respectively. In contrast, below this [Ca2] value
force, development by the sarcomeres will be somewhat higher
in MYBPC3mut and HCMmn compared with donor.
Effects of Protein Kinase A
Force measurements were repeated at a sarcomere length of
2.2 m in 32 MYBPC3mut cardiomyocytes (from 12 hearts), 19
HCMmn cells (from 8 hearts), and 24 donor cells (from 8 hearts)
after treatment with exogenous PKA to mimic saturated
-adrenergic receptor stimulation. PKA slightly reduced maxi-
mal and passive force in all groups (data not shown), while nH
was not altered. The minor decreases in force were not signifi-
cant and may be caused by deterioration of the preparation
quality during repeated activations. Treatment of cells with PKA
significantly reduced myofilament Ca2-sensitivity in all groups
(P0.0001 in 2-way repeated measures ANOVA). The PKA-
induced reduction in Ca2-sensitivity of force was significantly
larger in MYBPC3mut (0.910.11 mol/L) compared with
donor (0.470.08 mol/L), and intermediate in HCMmn
(0.730.12 mol/L; Figure 6A; interaction P0.009 in 2-way
repeated measures ANOVA). PKA abolished the initial differ-
Figure 2. Site-specific phosphorylation of car-
diac myosin binding protein C. A, Western blot
analysis with specific antibodies against phos-
phorylated sites in cMyBP-C. B, Significantly
lower phosphorylation was observed at Ser273
and Ser282 in HCMmn compared with donor,
while no significant differences in phosphoryla-
tion at Ser273, Ser282, and Ser302 were found
between MYBPC3mut and donor hearts.
*P0.05 versus donor in Dunn Multiple Com-
parison Test or Bonferroni post test.
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ence in Ca2-sensitivity of force between patient groups and
donor as shown in Figure 6A. Figure 6B illustrates that after
PKA, force development was depressed in patient cells com-
pared with donor both at maximal and submaximal [Ca2]
(interaction P0.005 in 2-way repeated measures ANOVA).
Interestingly, PKA pretreatment of cells significantly en-
hanced the sarcomere length-dependent change in Ca2-
sensitivity (EC50) in MYBPC3mut (4 hearts, 14 cells) and
HCMmn (4 hearts, 15 cells), but not in donor (4 hearts, 12
cells; Figure 7; P0.009 in 2-way ANOVA). The blunted
shift in EC50 on an increase in sarcomere length from 1.8 to
2.2 m in patient groups compared with donor cells at
baseline was absent on PKA pretreatment (Figure 7).
Discussion
This study is the first to compare both protein composition and
function of the sarcomeres in well-defined HCM patient groups
with MYBPC3 mutations and without an identified sarcomere
mutation. The observed differences in sarcomere function seem
to reflect the clinical HCM phenotype rather than the specific
MYBPC3 mutation. Despite normal LV systolic function, the
force generating capacity of the sarcomeres was lower and
sarcomere responsiveness to an increase in sarcomere length
was blunted (ie, reduced length dependent activation). The
perturbations in sarcomere function may contribute to HCM
disease progression.
Cardiac MyBP-C Haploinsufficiency is Unique for
HCM With MYBPC3 Mutations
Our study revealed that cMyBP-C haploinsufficency is not a
general feature of HCM. As cMyBP-C exerts a role in myofil-
ament assembly and integrity,24 the lower expression of
cMyBP-C may underlie disease pathogenesis by disruption of
myocardial structure. HCM patients with a MYBPC3 mutation
were younger (P0.05) than HCM mutation negative individ-
uals, which suggests that the sarcomere mutation itself is a
detrimental modifier of disease progression. In accordance,
Olivotto et al26 reported an increased risk to develop severe LV
dysfunction and progress to end-stage heart failure in patients
with an identified sarcomere mutation (both thin and thick
filament mutations) compared with mutation negative patients.
Cardiac remodeling, including cardiac myocyte disarray and
fibrosis, has been observed in homozygous cMyBP-C knockout
mice, in which cMyBP-C was completely absent.27,28 At 11
months of age heterozygous cMyBP-C null mice that only
expressed 75% of normal cMyBP-C content showed asym-
metrical septal hypertrophy and signs of fibrosis, while no
morphological changes were observed at 3 to 4 months of age.28
Future longitudinal studies should be performed to answer the
question if cMyBP-C haploinsufficiency exerts a detrimental
effect on the development of hypertrophic cardiomyopathy in
patients with MYBPC3 mutations.
Reduced Phosphorylation of PKA Target Proteins
Lower phosphorylation of cTnI compared with donor hearts
was evident in both HCM groups and may reflect a post-
translational phenotype-related protein modification. Low
phosphorylation of cTnI compared with nonfailing donor
hearts has been observed in previous studies in end-stage
failing hearts from patients with idiopathic or ischemic
dilated cardiomyopathy,21,29–31 and thus appears to be a
general feature of progressive cardiac disease consistent with
Figure 3. Phosphorylation forms of cardiac troponin (cTnI). A, Phosphorylation of cTnI (normalized to -actinin) was significantly lower
in MYBPC3mut and HCMmn compared with donor samples. B, Western blot with specific antibodies against the phosphorylated PKA
sites Ser22/23 on cTnI revealed significantly lower phosphorylation in both HCM patient groups than in donor. C, Cardiac samples
were separated on a Phos-tag acrylamide gel to demonstrate the distribution of un- (0P), mono- (1P), and bis- (2P) phosphorylated car-
diac troponin I. Minor differences in sample loading are present, but care was taken to load all samples within the linear range of cTnI
detection. D, Both HCM patient groups had relatively higher levels of un- and monophosphorylated cTnI and a lower level of bisphos-
phorylated cTnI compared with donor. *P0.05 versus donor in Dunn Multiple Comparison Test.
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down-regulation and desensitization of the -adrenergic receptor
pathway.32 Western blot analysis confirmed lower phosphorylation
at the PKA sites of cTnI in both MYBPC3mut and HCMmn samples
compared with donor (Figure 3B).
Phosphorylation of the other PKA target protein cMyBP-C
also was lower in the HCMmn group, but was relatively high in
MYBPC3mut samples (Figure 1D). cMyBP-C has 3 putative
phosphorylation sites (Ser273, Ser282, and Ser302) that are
substrates for PKA, protein kinase C, and calcium-calmodulin–
dependent kinase.33,34 Analysis of site-specific cMyBP-C phos-
phorylation using phospho-specific antibodies against these sites
(Figure 2) confirmed the “high” phosphorylation of cMyBP-C in
MYBPC3mut, as phosphorylation at all sites did not significantly
differ from the donor group. A significantly lower phosphory-
lation at Ser273 and Ser282 was observed in the HCMmn
samples compared with donor hearts. Similarly, a recent study
by Copeland et al17 reported a reduction in total cMyBP-C
phosphorylation in HCM myectomy samples to 39% of the
value found in nonfailing myocardium. Our analysis did not
reveal a significant difference in phosphorylated Ser302 between
MYBPC3mut, HCMmn, and donor samples (Figure 2B). Recent
studies indicated that Ser302 is phosphorylated by calcium-
calmodulin–dependent kinase, which is activated on an increase
in heart rate, rather than by PKA.35,36 Hence, the significantly
lower total cMyBP-C phosphorylation observed in HCMmn
compared with donor may be the result of reduced PKA-
mediated phosphorylation compared with nonfailing donor
myocardium. The divergent phosphorylation pattern of the PKA
targets, cTnI, and cMyBP-C in the MYBPC3mut samples may be
well-explained by an altered stoichiometry between protein level
and PKA expression or its activity. This is illustrated in Figure
1E, which shows that the level of phosphorylated cMyBP-C,
which reflects kinase activity, is independent of cMyBP-C
expression in the patient groups and significantly lower in both
MYBPC3mut and HCMmn compared with donor.
Lower Force Generating Capacity and Higher
Ca2-Sensitivity: Common Sarcomere Features
of HCM
Our data suggest that low maximal force generating capacity of
sarcomeres is a general feature of HCM patients, while passive
force is higher only in a few HCM samples with a MYBPC3
mutation (Figure 4). A recent study by Hoskins et al37 demon-
strated a 40% lower maximal isometric force in 6 HCM hearts
with mutations in MYBPC3, MYH7, or no identified mutation,
while passive stiffness of the cardiomyocytes was not different
Figure 4. Sarcomere force development at
a sarcomere length of 2.2 m. Force mea-
surements were performed at a sarcomere
length of 2.2 m in single cardiomyocytes
from 16 MYBPC3mut (67 cardiomyocytes), 8
HCMmn (38 cardiomyocytes), and 10 donor
samples (45 cardiomyocytes). The maximal
force generating capacity (Fmax; A) was
significantly lower in MYBPC3mut and
HCMmn compared with donor, while pas-
sive force (Fpas, B) did not significantly dif-
fer among groups. Force was measured at
maximal and submaximal [Ca2] to deter-
mine Ca2-sensitivity of force. C, Force at
submaximal [Ca2] was normalized to the
maximal force at saturating [Ca2], which
was set to 1 and plotted against [Ca2].
Relative force-calcium relations of patient
groups were shifted to the left compared
with donor, indicative for a higher Ca2-
sensitivity of force. D, The [Ca2] at which
50% of maximal force is reached (ie, EC50)
was significantly lower in patient groups
compared with donor. D shows EC50 val-
ues for individual heart samples. In addi-
tion, steepness of the force-calcium rela-
tions (nH) was significantly lower in patient
groups compared with donor (C and E).
*P0.05 versus donor in Dunn Multiple
Comparison Test or Bonferroni post test.
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from donor. Thus, the significantly lower maximal force gener-
ating capacity appears to be characteristic for the clinical HCM
phenotype. Other intrinsic alterations within the sarcomeres,
which have been described in diseased myocardium (eg, sarco-
meric disarray, oxidative modifications) or a reduction of myo-
fibrillar density may explain the lower maximal isometric force.
Interestingly, HCM is regarded as a disease with hyperdynamic
LV function, which may evolve to end-stage failure with systolic
dysfunction.26 Our patient group showed normal systolic LV
function. Therefore, the hypocontractile sarcomeres may not
have a large impact on systolic performance, but may contribute
to disease progression of HCM.
In vivo studies in preclinical HCM patients reported diastolic
dysfunction as one of the earliest signs of cardiac dysfunction.6–9
In our previous studies in patients with diastolic heart failure (ie,
heart failure with preserved ejection fraction), we found that
passive stiffness is an important determinant of the high LV
end-diastolic pressures observed in diastolic heart failure.38 In
the present study, we did not find a significantly higher passive
stiffness in both HCM patient groups, although Fpas was higher
in several of the MYBPC3mut samples compared with nonfailing
donor (Figure 4B). A reduction in myofibrillar density, which
may be part of HCM myocardial remodelling, would mask
stiffening of sarcomeres. In order to separate mutation- from
remodelling-related changes in cardiomyocyte function, in our
future studies we will investigate myofibrillar density and
cardiomyocyte force characteristics in HCM in comparison with
patients with aortic stenosis-induced hypertrophy. These future
studies will reveal if stiffening of sarcomeres contributes to
diastolic dysfunction in (preclinical) HCM patients, and may be
a target for therapy in the early stage of HCM.
A higher Ca2-sensitivity of myofilaments has been reported
previously in end-stage dilated and ischemic human cardiomy-
opathy,16,30 and has been associated with lower PKA-mediated
Figure 5. Force measurements in Triton-permeabilized single cardiomyocytes. A, Single cardiomyocyte isolated from a MYBPC3mut heart
at a sarcomere length of 1.8 and 2.2 m. Bar indicates 10 m. Force was measured at 2 sarcomere lengths in cells isolated from 13
MYBPC3mut (43 cells), 8 HCMmn (36 cells), and 9 donor (32 cells) hearts. Cardiomyocyte force values were averaged per sample. B, Absolute
force (ie, tension) plotted against [Ca2] shows that force development at low [Ca2] (below 3.3 and 2.5 mol/L for a sarcomere length of 1.8
and 2.2 m, respectively) is higher in patient groups compared with donor, while force development above this [Ca2] is depressed in patient
groups compared with donor. n denotes number of cells. C, The length-dependent increase in Ca2-sensitivity of force was less in
MYBPC3mut and HCMmn patient groups compared with donors. *P0.05 versus donor in Dunn Multiple Comparison Test.
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phosphorylation of cTnI and cMyBP-C.21,29,30 Both cMyBP-C
and cTnI have a central role in regulating cardiac performance in
response to -adrenergic receptor stimulation as occurs during
exercise. Apart from changes in calcium handling (via phosphor-
ylation of L-type calcium channels, ryanodine receptors, and
phospholamban), which increase systolic force development,39
positive lusitropic effects (ie, increased relaxation) are in part
mediated via a reduction in myofilament Ca2-sensitivity and
increased cross-bridge cycling kinetics. PKA-induced myofila-
ment desensitization is mediated via phosphorylation of both
cTnI and cMyBP-C.40–42 PKA treatment abolished the initial
differences in EC50 among groups (Figure 6A), indicating that
the higher Ca2-sensitivity is because of lower phosphorylation
of cMyBP-C and cTnI. Apart from phosphorylation deficits, the
lower cMyBP-C expression in the MYBPC3mut group may alter
myofilament Ca2-sensitivity. A higher myofilament Ca2-
sensitivity has been reported in cardiomyocytes on extraction of
cMyBP-C and in cMyBP-C knock-out mice.40,43 This indicates
that apart from reduced PKA-mediated sarcomere phosphoryla-
tion, cMyBP-C haploinsufficiency in the MYBPC3mut group
may in part underlie the higher baseline Ca2-sensitivity.
The combination of a lower maximal force, higher Ca2-
sensitivity, and lower cooperativity of force development as
shown in Figure 5B indicates that the sarcomere differences
compared with nonfailing myocardium may lower systolic
function at high intracellular [Ca2] and may somewhat limit
myocardial relaxation at low [Ca2] in human HCM. Of note,
during increased cardiac stress, ie, after treatment with exoge-
nous PKA, HCM sarcomeres are hypocontractile at all calcium
concentrations compared with nonfailing donor hearts (Figure
6B), suggesting that perturbed sarcomeric properties of manifest
HCM may compromise systolic performance of the heart, in
particular during increased cardiac load.
Blunted Length-Dependent Activation in HCM
In addition to the regulatory effect of the sarcomeres during
increased sympathetic activity, the Frank-Starling mechanism,
which provides a beat-to-beat regulating mechanism of systolic
performance on enhanced ventricular filling (ie, increased end-
diastolic volume), is caused by an increase in both maximal
force generating capacity and Ca2-sensitivity of the sarco-
meres.44,45 Again, one of the possible mediating proteins in-
volved in the increased force development on an increase in
sarcomere length is cMyBP-C, as the length-dependent activa-
tion of force was significantly blunted in muscle strips from
cMyBP-C deficient mice.40 Interestingly, assessment of regional
myocardial function with cardiac magnetic resonance imaging
indicated blunting of the Frank-Starling mechanism in MYBPC3
mutation carriers compared with healthy individuals,8 which
may involve mutant MYBPC3. However, as similar changes in
length-dependent activation of the sarcomeres were observed in
patients with and without MYBPC3 mutations, the blunted
length-dependent increase in myofilament Ca2-sensitivity most
likely is related to the secondary HCM disease phenotype.
Konhilas et al46 showed reduced length-dependent activation in
myocytes from mouse myocardium harboring skeletal TnI,
which lacks the PKA phosphorylation sites. Moreover, the
length-dependent activation was enhanced on treatment with
PKA in cardiomyocytes from nontransgenic mice.46 Likewise,
in the present study, incubation with PKA restored the length-
dependent increase in Ca2-sensitivity in both HCM groups to
the response observed in donor (Figure 7). As PKA incubation
Figure 7. Effect of protein kinase A on length-dependent activa-
tion. The blunted length-dependent activation in patient groups
was normalized to donor values on pretreatment with protein
kinase A. *P0.05 versus donor; #P0.05 effect of protein
kinase pretreatment in Bonferroni post test analyses.
Figure 6. Effect of protein kinase A on myofilament Ca2-
sensitivity. A, Treatment of cells with exogenous protein kinase A
(PKA) significantly reduced Ca2-sensitivity of force in all groups
(12 MYBPC3mut, 32 cells; 8 HCMmn, 19 cells; and 8 donors, 24
cells). The change in Ca2-sensitivity of force (ie, EC50difference
between EC50 before and after PKA) was largest in MYBPC3mut
and smallest in donor hearts. The difference in Ca2-sensitivity of
force (EC50) among groups before PKA was abolished on PKA
treatment. B, After PKA treatment, myofilament force development
at a sarcomere length of 2.2 m was lower at maximal and sub-
maximal [Ca2] in MYBPC3mut and HCMmn, compared with donor.
n denotes number of cells. *P0.05 versus donor; #P0.05 effect
of PKA in Bonferroni post test analyses.
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lowered baseline Ca2-sensitivity, likely via phosphorylation of
cTnI, this might restore the margin of Ca2-sensitivity response
and allow for an increase on increased sarcomere length.
Limitations and Clinical Implications
As all HCM patients received drug therapy, we cannot exclude
effects of medication on the outcome of our study. Recently, we
have shown that -blocker therapy (bisoprolol) in pigs with a
myocardial infarction corrected sarcomeric dysfunction in in-
farct animals to levels found in sham animals.47 Moreover,
maximal force development of single cardiomyocytes was sig-
nificantly higher in heart failure patients who received chronic
-blocker treatment compared with patients who did not receive
-blockers.48 Hence, the lower maximal force of HCM cardio-
myocytes compared with donors may be somewhat underesti-
mated because of positive effects of -blocker treatment. As
overall drug treatment was similar in the HCM patient groups
we assume that any effect of medication will be equal in both
groups.
In conclusion, investigation of protein composition and func-
tion of the sarcomeres in a large well-characterized HCM patient
group with MYBPC3 mutations and without identified mutations
revealed cMyBP-C haploinsufficiency to be unique for HCM
patients with MYBPC3 mutations, while lower protein phos-
phorylation compared with nonfailing myocardium appears
common for the clinical HCM phenotype. The hypocontractile
sarcomeres seem to be characteristic of hypertrophic cardiomy-
opathy patients, as our previous studies in cardiomyocytes from
patients with ischemic and idiopathic cardiomyopathy showed
similar maximal force development as observed in nonfailing
donor cells.31 A lower PKA-mediated protein phosphorylation
may in part underlie differences in sarcomere function between
human HCM and nonfailing hearts, yielding a higher Ca2-
sensitivity and a blunted length-dependent sarcomere respon-
siveness, which may explain defects in activation and relaxation
of the heart muscle in HCM patients with normal LV function
and diastolic dysfunction.
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CLINICAL PERSPECTIVE
Familial hypertrophic cardiomyopathy (HCM) is the most frequent inheritable cardiac disease, with a prevalence of
approximately 1/500. Clinical presentation is very heterogeneous, as some patients reach old age with virtually no symptoms or
events, while others progress to end-stage heart failure or die at young age from sudden cardiac arrest. To develop a targeted
treatment to prevent or delay HCM, it is highly relevant to understand the pathophysiology of this disease. HCM is frequently
caused by mutations in genes encoding sarcomeric proteins. Mutations in the MYBPC3 gene encoding cardiac myosin-binding
protein C (cMyBP-C) represent more than 40% of all HCM cases. Previous in vivo studies in preclinical HCM patients indicate
that sarcomeric mutations initiate early modifications in myocardial function. We studied if changes in sarcomeric properties in
HCM depend on an underlying protein mutation by comparing cardiac samples from patients carrying a MYBPC3 mutation with
mutation negative HCM patients. Data from these 2 HCM patient groups were compared with hearts from nonfailing donors.
Force measurements in single cardiomyocytes revealed reduced maximal force in both HCM groups compared with healthy
hearts. Moreover, the length-dependent activation (ie, Frank-Starling mechanism) was blunted in HCM hearts compared with
healthy myocardium. A significant reduction in cMyBP-C protein level (cMyBP-C haploinsufficiency) was found only in
patients carrying a MYBPC3 mutation. cMyBP-C haploinsufficiency may exert a detrimental effect on HCM development, as
average age of these patients was lower compared with mutation negative HCM patients. Overall, we found hypocontractile
sarcomeres in HCM patients with normal LV systolic function irrespective of the mutant protein. These perturbations in
sarcomere function may contribute to HCM disease progression.
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